Gastroenterology

29 HUMAN BONE MARROW DERIVED MESENCHYMAL STEM CELLS MEDIATE IMMUNOSUPPRESSION IN EXPERIMENTAL CROHN’S DISEASE BY SECRETING PROSTAGLANDIN E2 AND REPROGRAMMING MACROPHAGES TO AN ANTI-INFLAMMATORY PHENOTYPE




Locally injected mesenchymal stem cells (MSCs) are now an approved therapy in European Union for perianal Crohn’s disease (CD) fistulas, however, clinical studies have shown limited efficacy of systemic MSC therapy for luminal CD. Thus, we studied the SAMP-1/YitFc (SAMP), a chronic and spontaneous murine model of small intestine (SI) inflammation for treatment with human bone marrow derived MSC (hMSC). We previously reported that hMSCs injected intraperitoneally (i.p) into SAMP resulted in histologic, mucosal and radiologic healing (Dave M et al.

Source link




Related posts

Addition of bovine colostrum reduces frequency, duration of acute diarrhea

Newsemia

High-fat feeding reprograms maternal energy metabolism and induces long-term postpartum obesity in mice

Newsemia

Unraveling the Mystery of Hiccups

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy